KLRB1 and urinary bladder carcinoma: TIMER-based analysis showed that the mRNA expression of CD161 was lower in the tissue samples of most malignant tumors, like bladder cancer (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD) (Figure 1A).